Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OTMOGNCV)

• DOT Name: Ankyrin repeat and MYND domain-containing protein 2 (ANKMY2)
• Gene Name: ANKMY2
• UniProt ID: ANKY2_HUMAN
• Pfam ID: PF12796 ; PF01753
• Sequence:
  MVHIKKGELTQEEKELLEVIGKGTVQEAGTLLSSKNVRVNCLDENGMTPLMHAAYKGKLD
  MCKLLLRHGADVNCHQHEHGYTALMFAALSGNKDITWVMLEAGAETDVVNSVGRTAAQMA
  AFVGQHDCVTIINNFFPRERLDYYTKPQGLDKEPKLPPKLAGPLHKIITTTNLHPVKIVM
  LVNENPLLTEEAALNKCYRVMDLICEKCMKQRDMNEVLAMKMHYISCIFQKCINFLKDGE
  NKLDTLIKSLLKGRASDGFPVYQEKIIRESIRKFPYCEATLLQQLVRSIAPVEIGSDPTA
  FSVLTQAITGQVGFVDVEFCTTCGEKGASKRCSVCKMVIYCDQTCQKTHWFTHKKICKNL
  KDIYEKQQLEAAKEKRQEENHGKLDVNSNCVNEEQPEAEVGISQKDSNPEDSGEGKKESL
  ESEAELEGLQDAPAGPQVSEE
• Function: May be involved in the trafficking of signaling proteins to the cilia.

Molecular Interaction Atlas (MIA) of This DOT

1 Drug(s) Affected the Post-Translational Modifications of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Valproate	DMCFE9I	Approved	Valproate decreases the methylation of Ankyrin repeat and MYND domain-containing protein 2 (ANKMY2).	[1]

14 Drug(s) Affected the Gene/Protein Processing of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Ciclosporin	DMAZJFX	Approved	Ciclosporin increases the expression of Ankyrin repeat and MYND domain-containing protein 2 (ANKMY2).	[2]
Tretinoin	DM49DUI	Approved	Tretinoin increases the expression of Ankyrin repeat and MYND domain-containing protein 2 (ANKMY2).	[3]
Acetaminophen	DMUIE76	Approved	Acetaminophen increases the expression of Ankyrin repeat and MYND domain-containing protein 2 (ANKMY2).	[4]
Cupric Sulfate	DMP0NFQ	Approved	Cupric Sulfate decreases the expression of Ankyrin repeat and MYND domain-containing protein 2 (ANKMY2).	[5]
Cisplatin	DMRHGI9	Approved	Cisplatin increases the expression of Ankyrin repeat and MYND domain-containing protein 2 (ANKMY2).	[6]
Estradiol	DMUNTE3	Approved	Estradiol decreases the expression of Ankyrin repeat and MYND domain-containing protein 2 (ANKMY2).	[7]
Ivermectin	DMDBX5F	Approved	Ivermectin decreases the expression of Ankyrin repeat and MYND domain-containing protein 2 (ANKMY2).	[8]
Quercetin	DM3NC4M	Approved	Quercetin decreases the expression of Ankyrin repeat and MYND domain-containing protein 2 (ANKMY2).	[9]
Calcitriol	DM8ZVJ7	Approved	Calcitriol increases the expression of Ankyrin repeat and MYND domain-containing protein 2 (ANKMY2).	[10]
Vorinostat	DMWMPD4	Approved	Vorinostat increases the expression of Ankyrin repeat and MYND domain-containing protein 2 (ANKMY2).	[11]
Decitabine	DMQL8XJ	Approved	Decitabine affects the expression of Ankyrin repeat and MYND domain-containing protein 2 (ANKMY2).	[12]
Niclosamide	DMJAGXQ	Approved	Niclosamide increases the expression of Ankyrin repeat and MYND domain-containing protein 2 (ANKMY2).	[13]
Benzo(a)pyrene	DMN7J43	Phase 1	Benzo(a)pyrene increases the expression of Ankyrin repeat and MYND domain-containing protein 2 (ANKMY2).	[14]
Trichostatin A	DM9C8NX	Investigative	Trichostatin A decreases the expression of Ankyrin repeat and MYND domain-containing protein 2 (ANKMY2).	[15]

References

• [1] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [2] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [3] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [4] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [5] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [6] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [7] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [8] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [9] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [10] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [11] A genomic approach to predict synergistic combinations for breast cancer treatment. Pharmacogenomics J. 2013 Feb;13(1):94-104. doi: 10.1038/tpj.2011.48. Epub 2011 Nov 15.
• [12] Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS One. 2012;7(12):e53003. doi: 10.1371/journal.pone.0053003. Epub 2012 Dec 27.
• [13] Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
• [14] Label-free quantitative proteomic analysis identifies the oncogenic role of FOXA1 in BaP-transformed 16HBE cells. Toxicol Appl Pharmacol. 2020 Sep 15;403:115160. doi: 10.1016/j.taap.2020.115160. Epub 2020 Jul 25.
• [15] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.